(−)-epigallocatechin gallate, a promising inhibitor of CBR1, enhanced the antitumor activity of daunorubicinol against hepatocellular carcinoma cells expressing high levels of CBR1 and corresponding xenografts [29]. The gene discussed is CBR1; the disease is hepatocellular carcinoma.